Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.

Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, Kida H.

J Infect Dis. 2019 Jul 16. pii: jiz244. doi: 10.1093/infdis/jiz244. [Epub ahead of print]

PMID:
31309975
2.

A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.

Kode SS, Pawar SD, Tare DS, Keng SS, Hurt AC, Mullick J.

Vet Microbiol. 2019 Aug;235:21-24. doi: 10.1016/j.vetmic.2019.06.005. Epub 2019 Jun 5.

PMID:
31282375
3.

Circulation and characterization of seasonal influenza viruses in Cambodia, 2012-2015.

Horwood PF, Karlsson EA, Horm SV, Ly S, Heng S, Chin S, Darapheak C, Saunders D, Chanthap L, Rith S, Y P, Chea KL, Sar B, Parry A, Ieng V, Tsuyouka R, Deng YM, Hurt AC, Barr IG, Komadina N, Buchy P, Dussart P.

Influenza Other Respir Viruses. 2019 Sep;13(5):465-476. doi: 10.1111/irv.12647. Epub 2019 Jun 28.

4.

Antivirals targeting the polymerase complex of influenza viruses.

Mifsud EJ, Hayden FG, Hurt AC.

Antiviral Res. 2019 Sep;169:104545. doi: 10.1016/j.antiviral.2019.104545. Epub 2019 Jun 25. Review.

5.

Virome heterogeneity and connectivity in waterfowl and shorebird communities.

Wille M, Shi M, Klaassen M, Hurt AC, Holmes EC.

ISME J. 2019 Jun 25. doi: 10.1038/s41396-019-0458-0. [Epub ahead of print]

PMID:
31239538
6.

Avian influenza in the Greater Mekong Subregion, 2003-2018.

Suttie A, Karlsson EA, Deng YM, Hurt AC, Greenhill AR, Barr IG, Dussart P, Horwood PF.

Infect Genet Evol. 2019 Jun 13;74:103920. doi: 10.1016/j.meegid.2019.103920. [Epub ahead of print] Review.

PMID:
31201870
7.

Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.

Farrukee R, Butler J, Reading PC, Hurt AC.

Antiviral Res. 2019 Aug;168:68-75. doi: 10.1016/j.antiviral.2019.05.009. Epub 2019 May 25.

PMID:
31132385
8.

Antiviral Therapy for the Next Influenza Pandemic.

Hurt AC.

Trop Med Infect Dis. 2019 Apr 18;4(2). pii: E67. doi: 10.3390/tropicalmed4020067.

9.

Meta-transcriptomics reveals a diverse antibiotic resistance gene pool in avian microbiomes.

Marcelino VR, Wille M, Hurt AC, González-Acuña D, Klaassen M, Schlub TE, Eden JS, Shi M, Iredell JR, Sorrell TC, Holmes EC.

BMC Biol. 2019 Apr 8;17(1):31. doi: 10.1186/s12915-019-0649-1.

10.

Antarctic Penguins as Reservoirs of Diversity for Avian Avulaviruses.

Wille M, Aban M, Wang J, Moore N, Shan S, Marshall J, González-Acuña D, Vijaykrishna D, Butler J, Wang J, Hall RJ, Williams DT, Hurt AC.

J Virol. 2019 May 15;93(11). pii: e00271-19. doi: 10.1128/JVI.00271-19. Print 2019 Jun 1.

11.

Untargeted metabolomics analysis of the upper respiratory tract of ferrets following influenza A virus infection and oseltamivir treatment.

Beale DJ, Oh DY, Karpe AV, Tai C, Dunn MS, Tilmanis D, Palombo EA, Hurt AC.

Metabolomics. 2019 Mar 1;15(3):33. doi: 10.1007/s11306-019-1499-0.

PMID:
30830484
12.

Human CD8+ T cell cross-reactivity across influenza A, B and C viruses.

Koutsakos M, Illing PT, Nguyen THO, Mifsud NA, Crawford JC, Rizzetto S, Eltahla AA, Clemens EB, Sant S, Chua BY, Wong CY, Allen EK, Teng D, Dash P, Boyd DF, Grzelak L, Zeng W, Hurt AC, Barr I, Rockman S, Jackson DC, Kotsimbos TC, Cheng AC, Richards M, Westall GP, Loudovaris T, Mannering SI, Elliott M, Tangye SG, Wakim LM, Rossjohn J, Vijaykrishna D, Luciani F, Thomas PG, Gras S, Purcell AW, Kedzierska K.

Nat Immunol. 2019 May;20(5):613-625. doi: 10.1038/s41590-019-0320-6. Epub 2019 Feb 18.

PMID:
30778243
13.

Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.

Koszalka P, Tilmanis D, Roe M, Vijaykrishna D, Hurt AC.

Antiviral Res. 2019 Apr;164:91-96. doi: 10.1016/j.antiviral.2019.02.007. Epub 2019 Feb 13.

14.

Cross-lineage protection by human antibodies binding the influenza B hemagglutinin.

Liu Y, Tan HX, Koutsakos M, Jegaskanda S, Esterbauer R, Tilmanis D, Aban M, Kedzierska K, Hurt AC, Kent SJ, Wheatley AK.

Nat Commun. 2019 Jan 18;10(1):324. doi: 10.1038/s41467-018-08165-y.

15.

A Divergent Hepatitis D-Like Agent in Birds.

Wille M, Netter HJ, Littlejohn M, Yuen L, Shi M, Eden JS, Klaassen M, Holmes EC, Hurt AC.

Viruses. 2018 Dec 17;10(12). pii: E720. doi: 10.3390/v10120720.

16.

Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem.

Tan HX, Jegaskanda S, Juno JA, Esterbauer R, Wong J, Kelly HG, Liu Y, Tilmanis D, Hurt AC, Yewdell JW, Kent SJ, Wheatley AK.

J Clin Invest. 2019 Feb 1;129(2):850-862. doi: 10.1172/JCI123366. Epub 2019 Jan 22.

17.

Virus-virus interactions and host ecology are associated with RNA virome structure in wild birds.

Wille M, Eden JS, Shi M, Klaassen M, Hurt AC, Holmes EC.

Mol Ecol. 2018 Dec;27(24):5263-5278. doi: 10.1111/mec.14918. Epub 2018 Nov 22.

PMID:
30375075
18.

Animal models used to assess influenza antivirals.

Mifsud EJ, Tai CM, Hurt AC.

Expert Opin Drug Discov. 2018 Dec;13(12):1131-1139. doi: 10.1080/17460441.2018.1540586. Epub 2018 Oct 30.

PMID:
30362841
19.

Neuraminidase inhibitor resistance in influenza: a clinical perspective.

Lee N, Hurt AC.

Curr Opin Infect Dis. 2018 Dec;31(6):520-526. doi: 10.1097/QCO.0000000000000498.

PMID:
30299356
20.

Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility.

Farrukee R, Zarebski AE, McCaw JM, Bloom JD, Reading PC, Hurt AC.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01081-18. doi: 10.1128/AAC.01081-18. Print 2018 Nov.

21.

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.

Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group.

N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197.

22.

Influenza A(H5N1) viruses with A(H9N2) single gene (matrix or PB1) reassortment isolated from Cambodian live bird markets.

Suttie A, Karlsson EA, Deng YM, Horm SV, Yann S, Tok S, Sorn S, Holl D, Tum S, Hurt AC, Greenhill AR, Barr IG, Horwood PF, Dussart P.

Virology. 2018 Oct;523:22-26. doi: 10.1016/j.virol.2018.07.028. Epub 2018 Jul 31.

PMID:
30075357
23.

A Review of DNA Vaccines Against Influenza.

Lee LYY, Izzard L, Hurt AC.

Front Immunol. 2018 Jul 9;9:1568. doi: 10.3389/fimmu.2018.01568. eCollection 2018. Review.

24.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.

Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, Huang W, Hurt AC, Leang SK, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A.

Antiviral Res. 2018 Sep;157:38-46. doi: 10.1016/j.antiviral.2018.07.001. Epub 2018 Jul 3.

25.

Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.

Matos AR, Resende PC, Miranda MD, Garcia CC, Caetano BC, Lopes JCO, Debur MC, Cury ALF, Vianna LA, Lima MC, Schirmer M, Gubareva L, Hurt AC, Brown DW, Siqueira MM.

Antiviral Res. 2018 Jun;154:35-43. doi: 10.1016/j.antiviral.2018.03.010. Epub 2018 Mar 28.

PMID:
29601892
26.

Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity.

Koutsakos M, Wheatley AK, Loh L, Clemens EB, Sant S, Nüssing S, Fox A, Chung AW, Laurie KL, Hurt AC, Rockman S, Lappas M, Loudovaris T, Mannering SI, Westall GP, Elliot M, Tangye SG, Wakim LM, Kent SJ, Nguyen THO, Kedzierska K.

Sci Transl Med. 2018 Feb 14;10(428). pii: eaan8405. doi: 10.1126/scitranslmed.aan8405.

PMID:
29444980
27.

New options to treat influenza B.

Hurt AC, Subbarao K.

Nat Microbiol. 2017 Oct;2(10):1342-1343. doi: 10.1038/s41564-017-0027-0. No abstract available.

PMID:
29046530
28.

The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.

Tilmanis D, van Baalen C, Oh DY, Rossignol JF, Hurt AC.

Antiviral Res. 2017 Nov;147:142-148. doi: 10.1016/j.antiviral.2017.10.002. Epub 2017 Oct 3.

29.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.

Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Odagiri T, Wang D, Zhang W, Meijer A.

Antiviral Res. 2017 Oct;146:12-20. doi: 10.1016/j.antiviral.2017.08.004. Epub 2017 Aug 10.

30.

Fc functional antibodies in humans with severe H7N9 and seasonal influenza.

Vanderven HA, Liu L, Ana-Sosa-Batiz F, Nguyen TH, Wan Y, Wines B, Hogarth PM, Tilmanis D, Reynaldi A, Parsons MS, Hurt AC, Davenport MP, Kotsimbos T, Cheng AC, Kedzierska K, Zhang X, Xu J, Kent SJ.

JCI Insight. 2017 Jul 6;2(13). pii: 92750. doi: 10.1172/jci.insight.92750. eCollection 2017 Jul 6.

32.

Uncomplicated Cystitis in an Adult Male Following Influenza B Virus Infection.

Allen RJ, Koutsakos M, Hurt AC, Kedzierska K.

Am J Case Rep. 2017 Feb 22;18:190-193.

33.

Selection of multi-drug resistant influenza A and B viruses under zanamivir pressure and their replication fitness in ferrets.

Oh DY, Panozzo J, Vitesnik S, Farrukee R, Piedrafita D, Mosse J, Hurt AC.

Antivir Ther. 2018;23(4):295-306. doi: 10.3851/IMP3135.

PMID:
28195559
34.

Influenza antivirals currently in late-phase clinical trial.

Koszalka P, Tilmanis D, Hurt AC.

Influenza Other Respir Viruses. 2017 May;11(3):240-246. doi: 10.1111/irv.12446. Epub 2017 Feb 28. Review.

35.

Assessment of the RNASound RNA Sampling Card for the Preservation of Influenza Virus RNA.

Lau H, Hurt AC.

Front Microbiol. 2016 Nov 2;7:1736. eCollection 2016.

36.
37.

Evidence for the Introduction, Reassortment, and Persistence of Diverse Influenza A Viruses in Antarctica.

Hurt AC, Su YCF, Aban M, Peck H, Lau H, Baas C, Deng YM, Spirason N, Ellström P, Hernandez J, Olsen B, Barr IG, Vijaykrishna D, Gonzalez-Acuna D.

J Virol. 2016 Oct 14;90(21):9674-9682. doi: 10.1128/JVI.01404-16. Print 2016 Nov 1.

38.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.

Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, Huang W, Lackenby A, Lee RT, Lo J, Maurer-Stroh S, Nguyen HT, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Tashiro M, Tilmanis D, Wang D, Zhang W, Meijer A.

Antiviral Res. 2016 Aug;132:178-85. doi: 10.1016/j.antiviral.2016.06.001. Epub 2016 Jun 3. Review.

39.

Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza.

Hurt AC, Kelly H.

Emerg Infect Dis. 2016 Jun;22(6):949-55. doi: 10.3201/eid2206.151037.

40.

Proposed Surveillance for Influenza A in Feral Pigs.

Dalziel AE, Peck HA, Hurt AC, Cooke J, Cassey P.

Ecohealth. 2016 Jun;13(2):410-4. doi: 10.1007/s10393-016-1126-8. Epub 2016 May 12.

PMID:
27174429
41.

Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness.

Oh DY, Hurt AC.

Front Microbiol. 2016 Feb 4;7:80. doi: 10.3389/fmicb.2016.00080. eCollection 2016. Review.

42.

Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.

Little K, Leang SK, Butler J, Baas C, Harrower B, Mosse J, Barr IG, Hurt AC.

Euro Surveill. 2015;20(45). doi: 10.2807/1560-7917.ES.2015.20.45.30060.

43.

Avian influenza in Australia: a summary of 5 years of wild bird surveillance.

Grillo VL, Arzey KE, Hansbro PM, Hurt AC, Warner S, Bergfeld J, Burgess GW, Cookson B, Dickason CJ, Ferenczi M, Hollingsworth T, Hoque M, Jackson RB, Klaassen M, Kirkland PD, Kung NY, Lisovski S, O'Dea MA, O'Riley K, Roshier D, Skerratt LF, Tracey JP, Wang X, Woods R, Post L.

Aust Vet J. 2015 Nov;93(11):387-93. doi: 10.1111/avj.12379.

PMID:
26503532
44.

Quantifying relative within-host replication fitness in influenza virus competition experiments.

Petrie SM, Butler J, Barr IG, McVernon J, Hurt AC, McCaw JM.

J Theor Biol. 2015 Oct 7;382:259-71. doi: 10.1016/j.jtbi.2015.07.003. Epub 2015 Jul 15.

PMID:
26188087
45.

Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses.

Bird NL, Olson MR, Hurt AC, Oshansky CM, Oh DY, Reading PC, Chua BY, Sun Y, Tang L, Handel A, Jackson DC, Turner SJ, Thomas PG, Kedzierska K.

PLoS One. 2015 Jun 18;10(6):e0129768. doi: 10.1371/journal.pone.0129768. eCollection 2015.

46.

Global circulation patterns of seasonal influenza viruses vary with antigenic drift.

Bedford T, Riley S, Barr IG, Broor S, Chadha M, Cox NJ, Daniels RS, Gunasekaran CP, Hurt AC, Kelso A, Klimov A, Lewis NS, Li X, McCauley JW, Odagiri T, Potdar V, Rambaut A, Shu Y, Skepner E, Smith DJ, Suchard MA, Tashiro M, Wang D, Xu X, Lemey P, Russell CA.

Nature. 2015 Jul 9;523(7559):217-20. doi: 10.1038/nature14460. Epub 2015 Jun 8.

47.

Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.

Panozzo J, Oh DY, Margo K, Morton DA, Piedrafita D, Mosse J, Hurt AC.

Antiviral Res. 2015 Aug;120:66-71. doi: 10.1016/j.antiviral.2015.05.007. Epub 2015 May 26.

PMID:
26022199
48.

Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility.

Farrukee R, Leang SK, Butler J, Lee RT, Maurer-Stroh S, Tilmanis D, Sullivan S, Mosse J, Barr IG, Hurt AC.

J Antimicrob Chemother. 2015 Jul;70(7):2004-12. doi: 10.1093/jac/dkv065. Epub 2015 Mar 18.

PMID:
25786478
49.

A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity.

Oh DY, Barr IG, Hurt AC.

PLoS One. 2015 Mar 4;10(3):e0118780. doi: 10.1371/journal.pone.0118780. eCollection 2015.

50.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.

Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M.

Antiviral Res. 2015 May;117:27-38. doi: 10.1016/j.antiviral.2015.02.003. Epub 2015 Feb 23.

Supplemental Content

Loading ...
Support Center